Business
Coherus Oncology is a commercial-stage oncology company built around LOQTORZI, an approved PD-1 inhibitor, and a mid-stage oncology pipeline.
Coherus turned net income positive, but operating cash flow worsened.
The read at a glance✓ Audited against SEC data
- Business mix — Commercial-stage oncologyNote
- Operating loss — ($181.1M), narrowerNote
- Net income — $168.0M, up sharplyOK
- Operating cash flow — ($138.5M), weakerWatch
- Equity — $61.0M from deficitOK
- Insiders — No purchases or salesNote
Where the revenue comes from
Fiscal 2025, as Coherus Oncology, Inc. reports it. History and quarterly detail are in the app.
- Toripalimab$40.8M
- Product And Service Other$1.3M
Leadership changes
From Coherus Oncology, Inc.'s own filings, the day they're filed.
- Michael Ryan · director · departureeff. 2025-04-23
- Rita A. Karachun · director · departureeff. 2025-04-23
- Paul Reider · Chief Commercial Officer · departureeff. 2025-04-16
Latest filings
- 8-K · Company announcement2026-08-28
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-08-17
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Coherus Oncology, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.